UNSPSC 51281623: Sisomicin

This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X55XSL74YQ. European Medicines Agency schedules Sisomicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10538MIG. Sisomicin generally arises in the molecular formula C19H37N5O7. The term SISOMICIN is an International Non-Proprietary Name or INN. SISOMICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule sisomicin under HS 29419000 and SITC 54139. As of Q4 2014, SISOMICIN remains the US FDA Preferred Term for this commodity. Sisomicin bears US NLM identifiers UMLS ID C0037209 and NCI Concept Code C72569. SMILES: O(C1C(O)C(OC2OC(=CCC2N)CN)C(N)CC1N)C1OCC(O)(C(NC)C1O)C.

UNSPSC 51281623 Sisomicin is a Commodity code nominally identifying a single aminoglycoside antibiotic, but the recent state and local opportunities tagged under it show little relevant activity — the sourced solicitations address naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, emergency medical and first aid supplies, and multi-source generic pharmaceuticals and OTC products, none of which align with procurement of sisomicin specifically. The code exhibits a mismatch between its narrow pharmaceutical scope and the broad health and pharmaceutical sourcing work actually being solicited by state and local buyers who have applied this tag.

State and local health agencies, county health departments, municipal fire departments, and statewide cooperative purchasing alliances have recently posted opportunities in this space. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for naloxone and drug deactivation systems; the City of Tampa issued an ITB on March 25, 2026 (due March 13, 2026, estimated $700,000) for medical and first aid supplies for the Fire Department Rescue Division, with a 5 percent SLBE bid discount up to $10,000; the Texas Health and Human Services Commission released an RFI on April 3, 2026 for direct-to-manufacturer pharmacy prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon. The geographic spread spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles extending reach to multiple jurisdictions. Buyers in this code's recent history are primarily state health and human services departments, county health systems, and municipal emergency services, signaling demand for pharmaceutical sourcing at scale — but sisomicin specifically does not appear as a line item in any of the sourced opportunities.